Genomtec S.A. debuts on the main market of the WSE—we advised on transfer of the listing
22.02.2023
On 16 February 2023 Genomtec S.A. debuted on the main market of the Warsaw Stock Exchange. The company’s shares had been listed since March 2021 on NewConnect. Genomtec S.A. is the 418th company to be listed on the main market of the WSE and the fourth debut on the main market in 2023. At the opening of the first trading session, the company’s shares rose more than 2%, to PLN 14.20.
Genomtec S.A., a medical technology company, was founded in 2016 in Wrocław. It conducts research and development on the application of isothermal methods in molecular diagnostics. The company’s flagship project is the mobile diagnostic system Genomtec ID.
Legal support for the process of transferring the listing of Genomtec S.A. from NewConnect to the main market of the WSE was provided by the Capital Markets practice at Wardyński & Partners. The work was carried out by Katarzyna Jaroszyńska and the project was headed by Marcin Pietkiewicz.